Pharma Mar (OTCMKTS:PHMMF – Get Free Report) is expected to be issuing its resultson Thursday, October 29th. Analysts expect the company to post earnings of $0.0038 per share and revenue of $53.02 million for the quarter.
Pharma Mar Stock Performance
OTCMKTS:PHMMF opened at $94.60 on Thursday. The stock has a 50-day simple moving average of $93.31 and a 200 day simple moving average of $94.65. Pharma Mar has a 52-week low of $77.41 and a 52-week high of $110.40.
About Pharma Mar
Pharma Mar, SA is a Spanish biopharmaceutical company focused on discovering, developing and commercializing innovative medicines derived from marine organisms. The company specializes primarily in oncology and maintains a research platform dedicated to identifying novel compounds with potential anticancer activity.
Its principal products include Yondelis (trabectedin), an anticancer treatment used in certain cases of advanced soft-tissue sarcoma and ovarian cancer, and Zepzelca (lurbinectedin), a therapy developed for patients with metastatic small-cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
Featured Stories
- Five stocks we like better than Pharma Mar
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.
